J Ment Health Disord. 2026;6(1):48–49.

Journal of Mental Health Disorders Commentary

Psychedelics: Historical Context, Emerging Science, and Future Clinical Frontiers

Vipul Janardan[1,*], Amit Khanna[1], Om Prakash[1], Anadrika Debbarma[1], Sidhant Mathur[1]

[1]Institute of Human Behaviour and Allied Sciences, New Delhi, India

[*]Correspondence should be addressed to Vipul Janardan, vipuljanardan777@gmail.com

Received date: September 03, 2024, **Accepted date:** March 23, 2026

Citation: Janardan V, Khanna A, Prakash O, Debbarma A, Mathur S. Psychedelics: Historical Context, Emerging Science, and Future Clinical Frontiers. J Ment Health Disord. 2026;6(1):48–49.

Abstract

Psychedelics a class of psychoactive compounds such as psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT) are undergoing a scientific renaissance. Studies since 2020 have shown their therapeutic promise in mental health treatment. This Commentary synthesizes historical usage, current neuroscientific and clinical evidence, and explores ethical and regulatory frontiers for future medical integration. While showing efficacy in treatment-resistant depression, PTSD, and addiction, these substances require rigorous, ethically guided scientific validation.

Keywords: Psychedelics, Mental Health, Treatment, Psilocybin, Lysergic acid diethylamide, Dimethyltryptamine, Therapeutic benefits, Depression, Anxiety

Introduction

Psychedelics, defined as substances that primarily exert their psychoactive effects via serotonin 5-HT2A receptor agonism and induce altered states of consciousness [1], have resurged in scientific inquiry, especially since 2020. Contemporary trials report strong antidepressant, anxiolytic, and neuroplastic effects when psychedelics are used in professionally guided therapy settings [2,3]. However, ongoing concerns include the risks of psychological destabilization, misuse outside clinical environments, and the ethical complexities of consent during altered states [4].

Historical Context

The use of psychedelics traces back millennia, particularly in Indigenous rituals for healing and spiritual transformation [5]. Western scientific interest peaked from the 1950s to 1970s but was abruptly curtailed by Schedule I criminalization. This legal status was influenced by sociopolitical fears rather than pharmacological evidence of harm, with government policy linking psychedelics to counterculture unrest rather than medical risk [4,6]. Recently, easing regulatory barriers reflect growing public health advocacy and scientific support [7].

Ethical Considerations

As psychedelics enter the realm of regulated medicine, ethical frameworks must evolve accordingly. Informed consent remains a contentious area, particularly given altered states of consciousness during sessions, requiring safeguards to protect autonomy [8]. Moreover, there is increasing concern about the cultural appropriation of Indigenous knowledge without due recognition or reciprocity [6]. Equally pressing is the need to avoid the commodification of psychedelic therapies by biotech companies, which risks privileging profit over patient welfare. To counter this, diversity-centered training protocols and community-informed consent models have been proposed to ensure equitable access and respect for cultural origins [6].

Current Research

Recent randomized controlled trials have shown that psychedelic-assisted therapies are effective for several mental health conditions. For instance, psilocybin has demonstrated a 65% remission rate in major depressive disorder after just two sessions [2]. A pivotal clinical trial published in The New England Journal of Medicine (NEJM) found psilocybin as

effective as the SSRI escitalopram for moderate-to-severe depression, with a more favorable side effect profile [9]. Neuroimaging studies reveal that psychedelics decrease hyperconnectivity in the brain's default mode network (DMN), a region implicated in depressive rumination [10]. This has been supported by newer research emphasizing the modulation of brain network dynamics through 5-HT2A agonism [11]. These substances also foster neuroplasticity enhancing the brain's capacity for adaptation and change. Beyond depression, psychedelics have shown promise in managing post-traumatic stress disorder [12], substance use disorders [13], and anxiety in patients facing life-threatening illness. Updated evidence supports the latter claim, with recent reviews emphasizing the existential relief provided to terminally ill patients [14].

Future Directions

Scaling up psychedelic medicine requires moving into Phase III clinical trials, standardizing therapeutic protocols, and institutionalizing clinician education. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are reviewing these therapies under 'Breakthrough Therapy' designations for accelerated approval [7]. Nonprofit organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS) are working to ensure that psychedelic therapy becomes accessible through initiatives like the Health Equity Program [15].

Conclusion

The psychiatric field is being reshaped by scientific evidence validating psychedelic therapy for treatment-resistant mental health conditions. These substances hold significant potential, but their promise must be realized within a tightly governed clinical, ethical, and regulatory framework. Continued research and inclusive policy development will be critical in ensuring safe, equitable implementation.

References

1. Roseman L, Erritzoe D, Nutt D, Carhart-Harris R, Timmermann C. Interrupting the psychedelic experience through contextual manipulation to study experience efficacy. JAMA Network Open. 2024 Jul 1;7(7):e2422181.

2. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021 May 1;78(5):481–9.

3. Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022 Nov 3;387(18):1637–48.

4. Noorani T, Davis O, Dymock A, Langlitz N, Schlag AK, Dyck E. Psychedelic humanities. Frontiers in Psychology. 2024 Aug 21; 15:1474064.

5. Winkelman MJ. Psychedelics and the future evolution of humanity. Journal of Psychedelic Studies. 2025;10(1): 4–21.

6. Langlitz N, Dyck E, Scheidegger M, Repantis D. Moral Psychopharmacology Needs Moral Inquiry: The Case of Psychedelics. Front. Psychiatry. 2021;12:680064.

7. Yaden DB, Johnson MW, Griffiths RR, Doss MK, Garcia-Romeu A, Nayak S, Gukasyan N, Mathur BN, Barrett FS. Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. Int J Neuropsychopharmacol. 2021 Aug 20;24(8):615–23.

8. Bradberry MM, Appelbaum PS, Gukasyan N. Informed Consent in Psychedelic-Assisted Therapy. Curr Top Behav Neurosci. 2024 Dec 31.

9. Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine. 2021 Apr 15;384(15):1402–11.

10. Mason NL, Kuypers KPC, Müller F, Reckweg J, Tse DHY, Toennes SW, et al. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology. 2020 Nov;45(12):2003–11.

11. Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, Kwan AC. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021 Aug 18;109(16):2535–44.e4.

12. Mitchell JM, Ot'alora G M, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al; MAPP2 Study Collaborator Group. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023 Oct;29(10):2473–80.

13. Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, et al. Identification of 5-HT_{2A} receptor signaling pathways associated with psychedelic potential. Nat Commun. 2023 Dec 15;14(1):8221.

14. Guerra LT, dos Santos RG, Hallak JE. Effects of ayahuasca on fear and anxiety: cross-talk between 5HT1A and 5HT2A receptors. Psychedelics. 2024 Dec 10;1(2):15–25.

15. Multidisciplinary Association for Psychedelic Studies. Health Equity. Available from: https://maps.org/health-equity/?allocation=health-equity.